Duchenne muscular dystrophy (DMD) is a recessive X-linked genetic disease caused by a mutation in the dystrophin gene. The new drug NS-065/NCNP-01 utilizing exon-skipping therapy targeting specific deletions has been used in a first-in-human trial for the treatment of DMD. We surveyed 10 pairs of DMD participants and their parents within this clinical trial via an iPad survey form and through interviews regarding their understanding of the trial, expectations, anxieties, and reasons for participating in the trial.
Introduction
Duchenne muscular dystrophy (DMD) is a rare, Xlinked, recessive genetic disease that occurs in about one in every 5000 male infants [1] . DMD causes progres-sive muscle weakness through repeated necrosis and regeneration of muscle fibers. This disorder is typically first noticed around 3-5 years of age with recurrent falls, and around 13 years of age, patients develop difficulties with motility, as well as a decline in cardiac and respiratory functions. Now that proper maintenance therapy is feasible, including the administration of steroids and rehabilitation, patients can be expected to live beyond 30 years of age; however, there is no comprehensive cure to date [2] . Recent advances have been made in the field of novel therapeutic drug development for DMD [3] . One innovative treatment method involves the expression of incomplete dystrophin induced by using antisense oligonucleotides to trigger an in-frame mutation through the transcriptional regulation of dystrophin protein deficiency, which is caused by an out-of-frame mutation of the dystrophin gene. Attempts have been made to apply this treatment method to DMD; Eteplirsen is the first approved drug for patients with DMD who can be treated by skipping exon 51, encompassing 13% of DMD patients [4, 5] . NS-065/NCNP-01 is a new drug providing a therapeutic effect by skipping the dystrophin gene exon 53, which was developed for DMD patients harboring a specific mutation within the dystrophin gene, which includes approximately 8%-10% of patients with DMD as reported by the National Center of Neurology and Psychiatry in Japan and Nippon Shinyaku Co., Ltd. [6, 7] . The number of patients expected to be treated by skipping exon 53 is secondary to those with a mutation in exon 51, and Takeshima et al. reported that both of these groups are of approximately the same percentage in Japan [8] . A first-in-human (FIH) clinical trial has been conducted in which this drug was administered to human patients with a targeted deletion in the dystrophin gene. The reason this drug was initially administered to these patients is that its properties do not allow it to be administered to healthy individuals possessing a normal dystrophin gene. As proof of concept in this trial, the intention was to confirm the expression of dystrophin in skeletal muscle cells via performance of muscle biopsies. However, because DMD is a progressive disease, only underage DMD patients have sufficient skeletal muscle mass necessary to evaluate the expression of dystrophin, which is why participation in this trial was decided upon by the subjects' parents as legal guardians. DMD patients are also reported to have an average intelligence quotient of 84 [9] , and thus it is often impossible for the trial subjects themselves to understand the content of assent. Efforts were also made to obtain voluntary informed assent of the patients, by explaining the study in a way that was tailored to the subjects' understanding, in accordance with the Guideline E11 of the Japan-US-EU International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use [10] .
It is rare for children to be enrolled as subjects in an FIH trial. We surveyed DMD patients participating in this NS-065/NCNP-01 FIH trial and their parents through interviews regarding their understanding of the trial, expectations, anxieties, and reasons for deciding to participate in the trial, with the aim of analyzing the participants' understanding as well as their anxiety levels and their parents' expectations. Needless to say, sufficient time to make decisions was given to the partic-ipants and their families before obtaining informed consent. We also inquired about what the participants and their families reported during the process of deciding upon participation. These results will provide basic knowledge and valuable information for upcoming clinical drug trials.
Materials and methods

Participants
The participants of this survey were DMD patients and their families enrolled in an early exploratory clinical trial of NS-065/NCNP-01. This clinical trial was operated at the National Center of Neurology and Psychiatry (NCNP) in Tokyo and was demonstrated as an investigator-initiated, single-institution, open-label, uncontrolled Phase 1 exploratory trial with the primary aim to determine the safety of NS-065/ NCNP-01. The recruited DMD patients were mainly non-ambulant patients with confirmed genetic diagnoses, as the purpose of this study was to evaluate safety. Muscle biopsy was performed under general anesthesia prior and post to the series of NS-065/NCNP-01 injections.
Questionnaire survey
This survey was conducted primarily during the hospitalized duration of this clinical trial, and prior to enrolment the purpose of this survey was explained to the parents, and their written informed consent was obtained. Informed assent was also obtained from the participants through efforts to gain their understanding via explanations presented in simple terms. The participants and their parents were surveyed separately, and care was taken to avoid the opinions from one interview influencing the answers of another. The survey questionnaire for the participants was created using a questionnaire creation application (MOMONGA Ò ) on a tablet with a format designed as user-friendly for children with muscle weakness, as their answer choices were selected by touching the screen. The medical doctors and clinical research coordinator engaging the clinical trial of NS-065/NCNP-01 were responsible for interviewing the subjects and assisting with the administration of the questionnaire. Participants chose the most applicable answers of the following described situations in the questionnaires: ''How would you feel in the following situations?", ''What do you dislike about this trial and about being in the hospital?", ''What have your parents told you about this hospitalization (trial)?" ''What do you think about this hospitalization (trial)?", and ''Who decided on this hospitalization (trial)?" as shown in Fig. 1 .
The questionnaire for the participants was comprised of multiple-choice questions, which included irrelevant questions to make them feel comfortable, such as the mention of a birthday present. For the parents, most items in the questionnaire consisted of multiple-choice questions. The questions included the following: ''How old is your child who is to participate in this trial?", ''Do you understand that this early exploratory trial may involve a dosage that is not necessarily expected to be therapeutically effective?", ''Did you hesitate in deciding to participate in this trial after hearing the explanation?", ''Have you spoken to your child about these matters?", ''What were your reasons for deciding to participate?", ''Have you explained the details of this illness to your child?", ''What made deciding to participate difficult?", ''Up to how long would you be able to commute one way to participate in a trial such as this one?", ''How have you discussed participation in this trial with your child?", ''How well do you think your child understands and accepts participation in this trial?" and ''Please mark the following scales according to your feelings" on a visual analogue scale (VAS) scale. In VAS scale, measuring the distance from the middle line to the center of the circle placed by the parents on the horizontal line, as shown in Fig. 2 . The VAS was formulated such that the middle line is neutral, and if expectations are higher the parents placed the circle to the right side, and if no expectation or anxiety was experienced the circles were placed to the left side. The institutional review board of the NCNP provided their approval for this study to be conducted following a review (approval number: A2013-094).
Results
Participants' backgrounds
Cooperation was obtained from 20 individuals, 10 boys with DMD and 10 parents, who participated in the NS-065/NCNP-01 early exploratory clinical trial from September 2013 to April 2015. The mean age ± standard deviation (range) of the participants at the time of answering the questionnaires was 11.3 ± 3.09 (6-16) years. Three of the participants were ambulatory, and seven were not. All the participants answered the questionnaires on their own. The questionnaires for the parents were answered by mothers in eight cases, the father in one case, and both parents in one case. The participants' residences covered a wide area in Japan, ranging about from 30 to 1050 km from NCNP. For safety monitoring, participants were hospitalized for 12 weeks; due to this long hospitalization period, some of the participants had to withdraw their school temporally, took classes in the hospital during the clinical trial period.
Participants' questionnaire answers
The summary of answers given by the participants is presented in Fig. 3 . For the series of items related to ''What do you dislike about this trial or about being in the hospital?". The item most commonly answered as ''Sad/Dislike" was ''Not being able to attend school" for five of the participants, followed by ''The long period of hospitalization" for three of the participants. Only two participants answered ''Sad/Dislike" to the question of ''the tests to examine the muscle."
In response to the question ''Who decided on this trial and hospitalization?", 3 boys answered ''Myself", two answered ''My parents and myself", and the remaining five answered ''My parents". Thus, half of the participants answered that they took part in the decision to participate in the trial.
For the series of items related to ''What have your parents told you about this hospitalization (trial)?", 8 of 10 participants answered, ''Do your best until the end", and four of them also answered, ''You can quit at any time if you do not like it." Eight of 10 participants answered, ''The drug might work," and within these participants, five answered ''The drug might not work" as well. 
Parents' questionnaire answers
The summary of results is shown in Fig. 4 . In response to the question ''Do you understand that this exploratory phase trial may involve a dosage that is not necessarily expected to be therapeutically effective?", all parents answered," I understand" or ''I somewhat understand."
For the question ''Did you hesitate in deciding to participate in this trial after the explanation?", 7 out of 10 of the parents answered, ''I did not hesitate at all" or ''I did not hesitate much", and three answered ''I hesitated a bit" or ''I hesitated". For the question, ''What were your reasons for deciding to participate?", 3 parents answered, ''Strongly applies" or ''Applies" to the reason ''Because my child desired to participate." For the items ''Because the investigational new drug might work" and ''Because my child might be included in future clinical trials using this drug," all parents answered, ''Strongly applies" or ''Applies".
With regard to informing the participants about their disease, parents were asked ''Have you explained the details of this illness to your child?" to which no parents answered ''Not explained anything"
To the question ''What made deciding to participate difficult?", physical and mental burden on the child were chosen by 9 and 8 parents, respectively, and seven parents selected ''muscle biopsy."
In terms of the VAS scale result, all answers were placed together for the entire proportion, as shown in Fig. 5 . When parents were asked to indicate how anxious they were about the therapeutic or side effects of the drug on a VAS scale, the expectations of a positive effect were found to outweigh anxiety concerning side effects.
Discussion
The main objective of a Phase-I trial at the initial stage of a clinical study during the development of a new drug is to establish the safety and tolerability of the drug being studied and to evaluate its pharmacokinetics and dose-response relationship. Such trials are usually conducted in healthy adults; however, if a DMD study drug such as NS-065/NCNP-01 targeting a specific mutation in the dystrophin gene is administered to healthy adults lacking the mutation, there is the risk of causing damage to health. Patients exhibiting specific dystrophin gene mutations are therefore recruited as subjects for such a Phase-I trial stage when there is a need to evaluate efficacy. Similarly, in the development of drugs for the treatment of malignant tumors, in which the investigational drug is administered only to patients from the Phase-I trial stage due to its toxicity, it has been reported that 85% of participating patients expected a therapeutic effect despite receiving an explanation that a therapeutic effect is not guaranteed, and only 22% of these patients expected to actually experience a therapeutic effect. This result indicates that patients participate in clinical studies with a hope for a therapeutic effect while understanding that there could be no effect at all, and it was also noted that there could be an association between their mental health and expectations of a therapeutic effect [11] .
The participants' decision to participate and related anxiety
In this study five out of 10 participants participated in the trial of their own volition, with five indicating this by answering the question regarding who made the decisions regarding their participation with ''My parents and myself" or ''Myself"; the mean age of these participants was 12.6 years. Comparing this group, the mean age of the participants who answered ''My parents" was 10.0 years, suggesting a tendency for older participants having a positive attitude concerning decisionmaking. Furthermore, the answers ''I want to cure my illness by doing my best with the tests and injections" and ''I think the drug will work for me" were both chosen by up to nine of the participants. Four out of 10 participants had not been informed of the name of their disease or given any details of their own disease. Concerning the disease; we expected that these participants would experience strong anxiety, however due in part to small sample size, no fixed trend was identified. Moreover, none of the participants considered quitting the trial, which also indicated active participation. The parents' expectations were also considered to have an impact on the participants' active participation because 7 of 10 of the participants agreed with the statement ''I want everyone to be pleased by me doing my best to participate". In addition, nine of the participants responded ''I don't care" and only one participant answered ''Sad/ Upset" to the question ''How would you feel in the following situations: when being told that you will continue to receive this drug permanently?" These results also indicate active participation.
The answers to the question, ''How would you feel in the following situations: when told that the drug you are receiving might not work well for you?" eight participants chose ''I don't care" In contrast, 6 of the participants answered ''Happy/joyful" to the question ''When you hear that the drug you are being injected with might also help other people," and seven participants selected ''I think so" in response to ''What do you think about this hospitalization (trial)?" with ''I want everyone to be pleased by me doing my best to participate". These answers might indicate that pleasing others -including their parents -is more important to the participants than drug efficacy. The DMD clinical trial participants are subjected to much stress derived from a variety of examinations as well as changes to their environment that might cause additional anxiety. In the NS-065/NCNP-01 trial, muscle biopsies were particularly stressful to the participants. Evaluation of dystrophin expression via muscle biopsy was a one of the major endpoints of the trial due to its importance for evaluating the efficacy of the investigational drug. In this clinical trial, muscle biopsies were conducted at least twice to make a comparison within the trial subjects before and after receiving the study drug. As muscle biopsy was likely a highly stressful endpoint for the participants, we expected that the muscle examination would be an aspect of the study that was generally disliked by the participants. However, in response to the question ''What do you dislike about this trial and about being in the hospital?" -only two participants answered ''Sad/Dislike" in reference to the muscle examinations, with the remainder answering ''I don't care." At this point in time, all the participants had already undergone muscle biopsy. In contrast, 7 out of 10 parents mentioned the requirement for muscle biopsies as an issue when deciding to participate in the trial, and indicated the need to fully examine the necessity of muscle biopsies and the feasibility of this choice as an endpoint. Considering this discrepancy, it is likely that the participants have little memory of the muscle biopsy as it is generally performed under general anesthesia.
Parents' expectations and explanations
When evaluating the parents' expectations regarding the study drug's effect it was suggested that expectations were extremely high. Even though all parents in this survey understood the possibility that the children would be divided into different dosage groups that were unlikely to exhibit a therapeutic effect, all answered that they were participating ''because the study drug might work." The impact of the parents' expectations regarding this new drug is demonstrated by 7 of 10 answering ''I did not hesitate at all" or ''I did not hesitate much" with regard to their decision to participate.
When the parents were asked how long they would be able to commute one way to visit a hospital, six parents answered ''distance (time) is of no particular concern," which suggested high expectations of the trial results. The VAS results indicated a tendency of higher expecta-tion as parents tended to select the circle on the right, which supported the implication of high expectations.
A survey of 573 parents participating in 18 pediatric clinical research studies conducted by the Clinical Investigation Center in France between 2004 and 2007 reported that the primary reason that parents decided to participate in a clinical trial was the potential of a direct benefit to their child; however, although all of the parents considered that low risk to their child was the most important factor when their child was healthy, only 70.2% of parents of sick children and 60.8% of parents of children with a serious disease answered that low risk to their child was the most important factor [12] . It is likely that this same trend exists in this clinical trial of NS-065/NCNP-01, in which parents decided that their children should participate with an expectation of greater benefit versus risk for their child. Furthermore, even when the parents understood that efficacy could not be guaranteed, they all opted for the possibility that their child would be included in future clinical trials as one of their reasons for deciding to participate. This indicates that the possibility of further clinical trials was an important factor in deciding participation. Three parents answered ''I hesitated/I hesitated a bit", with one of them explaining that ''When we heard about this study, we had no hesitation. But, after knowing the details concerning the trial, we began to hesitate as to whether or not we would participate". Being informed and subsequently delivering consent is of utmost importance for making rational decisions concerning the welfare of a family member in such a clinical trial.
Conversely, although 7 of 10 parents told their children in this trial that the study drug could work, only four of these parents informed their children that the study drug might not work, with the other three explaining only the drug's efficacy. There was the discrepancy between the number of participants and parents who answered ''the study drug might not work", as one family didn't match their answers. We hypothesize that one of the reasons causing this discrepancy was because the participant was the youngest boy of the group, and might have misunderstood this question or the situation. Side effects were only explained by two parents, suggesting that the parents' explanations to their children tended to be biased.
Points to consider for future DMD clinical trials
Furthermore, although all the participants answered that their parents had told them to ''do your best until the end", 4 of 10 participants answered that they had not been told by their parents that they ''can quit at any time if you do not like it". Both the parents and participants were told at the time of providing consent and assent that it was possible to withdraw from the trial after it had commenced, which also revealed the problem that the participants may not have had a proper explanation concerning the right to withdraw, and furthermore, their parents might have provided biased information. In another clinical trial involving families, participants were examined as to whether or not acceptance of withdrawing from a trial resulted in differences in the subjects' anxiety, and the results showed that the participants and their families who participated in trials actively or from a neutral standpoint could be less prone to mental stress if they are sufficiently supported by the research team [13] . Unfortunately, no conclusions regarding this could be drawn from our survey due to various limitations, including small sample size. Exonskipping therapy targets a limited population among DMD patients, and the number of participants is quite small. In addition, our survey was mainly comprised of multiple-choice questions; thus, participants had a limited number of answers to choose from. To compensate for this limitation, and in an aim to collect various opinions, free answer space was provided for participants and their parents, however, no participants added extra opinions. Finally, this survey was self-reported, and misapprehensions might be resulted due to the small sample size.
Conclusion
DMD is a disease for which available effective treatments are limited and in such a situation participating in the clinical trial of new drugs is one of the greatest hopes for patients and families. This study showed that participants and families positively participated in the NS-065/NCNP-01 trial. However, caution should be taken when family expectations are high, as there is a chance that the patients will receive biased information from their families, and in trying to meet their families' expectations, a risk is posed for an environment eliminating their wishes or anxiety. The results of this survey could, therefore, serve as valuable information for designing future clinical trials for muscular dystrophy and offers suggestions for care for participants and families.
